Compound Nevus with Severe Dysplastic Feature in Mixed Germ Cell Tumor: A Case Report

Document Type : Case Report


1 Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

2 Urology Department, Tehran University of Medical Sciences, Tehran, Iran

3 Otolaryngology department, Shahid Beheshti University of Medical Sciences, Tehran, Iran


Testicular cancer is the most common tumor of the genital tract of 18-39 years-old men; its incidence is increasing in recent decades. However, the 10-year survival rate of testicular cancer is above 90%, which can result from radiation and chemotherapy used to treat patients. Testicular cancer patients are at risk for secondary malignancies; in this regard, the effects of radiation are brighter than chemotherapy. Recent studies reported melanoma and malignant skin changes as secondary malignancies in these people.
Case presentation
this study tends to introduce a 31-year-old patient with a mixed germ cell tumor and severe dysplastic changes in a compound nevus. Our patient had long-term exposure to sunlight and numerous skin nevi before the diagnosis of testicular cancer.
 The findings do not certainly support the relationship between the emergence of a nevus with severe dysplastic changes and testicular tumor.


  • Testicular cancer patients are at risk for secondary malignancies.
  • These patients are better to avoid ultraviolet rays, as much as possible.
  • Recent studies reported melanoma and malignant skin changes as secondary malignancies in this patient.


Main Subjects


Testicular cancer is the most common tumor of the genital tract of 18-39 years-old men; its incidence is increasing in recent decades (1, 2). The ten-year survival rate of testicular cancer, despite other malignancies in adults, is above 90% (3, 4), which can result from chemotherapy (5), and radiotherapy in its treatment. Radiotherapy and chemotherapy used in these patients are associated with the risk of side effects. Some studies reported heart and lung complications, nephrotoxicity, neurotoxicity, and gonadal toxicity at 5-10 years after chemotherapy or radiotherapy in patients with testicular cancer (6, 7). On the other hand, these patients are at risk for secondary cancers. In this regard, the effects of radiation are brighter than chemotherapy; some studies reported that the risk of solid tumors in patients who have radiotherapy is 1.7-3.5 times greater than others (6, 8). Recent studies on the incidence of secondary malignancies after chemotherapy in these patients show the increased risk of solid tumors (tumors of kidney, thyroid, bladder, prostate, melanoma, etc.) in patients with non-seminoma germ cell tumors (NSGST)  after chemotherapy based on cisplatin (9). Since recent studies report melanoma as a secondary malignancy of testicular tumors, skin examination is seriously recommended in these patients (10).


Case presentation

The patient was a 31-year-old, married man who had a daughter; about a year ago. The informed consent was completed by the patient to report the case, and the case was reported based on CARE guidelines. The patient experienced vague pain and increased size of left testis before admission (May 2014). The patient had no history of previous similar pain, trauma, fever, chills, unsafe sex, discharge from meatus, weight loss, and constitutional symptoms. The patient also complained of occasional non-productive cough during this period and did not tend to prevent or treat. The patient had no history of the underlying disease and previous surgery. The patient did not smoke or take certain medications. His younger brother had died at the age of 14 years because of leukemia. Physical examination only revealed numerous small and pale spots in the face, neck, and Thunder mass of the left testis. (Figure 1).



Figure 1. Compound melanocytic nevus


About a month after surgery, 4 times of chemotherapy with cisplatin, bleomycin, and etoposide-containing regimen began for the patient after saving sperm. CT scan of the lungs, abdomen, and pelvis did not report any pathological lesions. The requested tumor markers decreased after surgery and were within the normal range after chemotherapy. During visits at determined times, the patient complained of back pain and right shoulder due to trauma for which conservative treatments were considered. Liver enzymes were requested for the patients, which were within normal ranges. Since the pain was not relieved, a bone scan was done for the patient; the scan reported no pathologic case other than a lesion caused by trauma in the right shoulder. 

About a year after the first visit (May 2015), the patient noticed that one of the nevi on his neck started to change color and got bigger; however, he has not followed up. In one of the regular visits for follow-up, the patient was referred to an otolaryngologist due to an obvious change in color and size of that nevus compared to other nevi and its irregular margins. The nevus prone to malignant melanoma was examined by excisional biopsy with sufficient margins. Pathologic results were reported as compound nevus with the severe dysplastic feature. Because the margin of the excisional biopsy was not involved, the dermatologist only recommended regular and closed follow-up. Currently, no pathologic case has been reported in the last and periodic examinations.



In the United States, testicular cancer is the most common cancer among men aged 20 to 40 years and the second malignancy after leukemia at the age of 15 to 19 years. Bilateral germ cell tumor incidence is estimated at 2%. The incidence of germ cell tumor is growing worldwide. Four proven risk factors of testicular cancer include cryptorchidism, family history, personal history, and intratubular germ cell neoplasia (ITGN). Testicular tumors are divided into two general categories: NSGST and seminoma germ cell tumor (SGST). Testicular cancer occurs in the form of a painless testicular enlargement. Ultrasound and measurement of tumor markers such as LDH, BHCG, and AFP help diagnosis of testicular tumors. Several therapies are currently used for testicular tumors. Radical orchiectomy is the main treatment of this malignancy and it is used based on the final diagnosis, radiotherapy, and chemotherapy in the treatment (11). Antigens of melanoma detected by autologous T cells or antibodies include mutant tumor antigens such as mutant pl6 [CDKN2A] and antigens of cancer/testis family shared tumor-specific such as MACE-I, MAGE, and NY-ESO-I as well as cell type-specific differentiation antigens. High incidence of melanoma and dysplastic nevi in patients with immunodeficiency support the hypothesis that melanoma is an immunogenic tumor. Dysplastic nevi are also likely to become malignant types of nevi (12).

The ten-year survival rate of testicular cancer is over 90% (3-5). Due to the high survival rate of these patients compared with other malignancies of adults and the young age of most patients as well as the higher risk of other malignancies in these people, it is important to consider periodic examinations for these people. Several studies have been conducted on the effect of chemotherapy and radiotherapy in long run on secondary malignancies in these patients. Most studies consider esophageal cancer, gastric cancer, malignant melanoma, leukemia, Hodgkin's lymphoma, thyroid cancer, kidney cancer, and soft tissue sarcoma as secondary malignancy of testicular cancer (13). The relationship between dysplastic nevi and germ cell tumors was first reported in four patients in 1988. Epidemiologic studies suggest an increased incidence of germ cell tumors and malignant melanoma at high social levels. On the other hand, risk factors of malignant melanoma include exposure to ultraviolet rays, white phenotype, the number of nevi, and genetic factors (14, 15). According to Lorenzo Richiardi, although genetic factors are involved in the development of testicular cancer, little is known about effective genes (16, 17). S.D. Fossa showed that patients who underwent radiation were at increased risk of solid tumors, particularly lung tumors, malignant melanoma, and gastric tumor compared with others (6). The origin of malignant melanoma is not clear in patients with testicular cancer; however, it may be due to changes in skin factors (13). Despite the increase in solid malignancies in people who underwent radiotherapy for testicular tumors, a clear relationship was reported between chemotherapy and the incidence of solid malignancies. However, the increased risk of skin malignancies following chemotherapy should be considered in the future (18, 19). The incidence of multiple atypical nevi was significantly higher than the control group in Raghavan (20). The patient examined in this report had multiple nevi of different sizes in all regions of the skin; before the development of testicular tumors, no change occurred in size. Due to job specifications, long-term exposure to sunlight, which can be a risk factor for melanoma and other skin malignancies, is seen in the history of this patient. Although most studies consider radiotherapy as a factor of secondary malignancies following testicular tumor, the patient did not undergo radiotherapy. The risk of skin malignancies was higher in patients receiving cisplatin-based chemotherapy than others (9). According to studies, physicians should consider secondary malignancies in reviews and examinations and periodic follow-ups of patients with testicular tumors. In particular, skin examination should be taken seriously due to the importance of early detection of changes in previous nevi or creation of new nevi. These patients are better to avoid ultraviolet rays, as much as possible. However, there is no specific guideline for the follow-up of melanoma in patients with testicular cancer.



Since the patient examined in this study had long-term exposure to sunlight and numerous skin nevi before the diagnosis of testicular cancer, findings do not certainly support the relationship between the emergence of a nevus with severe dysplastic changes and testicular tumor.


 Authors’ Contribution

All authors contributed equally.



Special thanks to the Urology Research Center (URC), Tehran University of Medical Sciences (TUMS).


Conflict of interest

All authors claim that there is not any conflict of interest.



There is no funding.


Ethical Statement

All authors ensured our manuscript reporting adheres to CARE guidelines for reporting of case reports. The patient agreed to report the case by signing the informed consent.


Data availability

Data will be provided by the corresponding author on request. 




AFP          Alpha-fetoprotein

CT            Computed tomography

HCG         Human chorionic gonadotropin

ITGN        Intratubular germ cell neoplasia

LDH         Lactate dehydrogenase

NSGST     Non-seminoma germ cell tumor

SGST        Seminoma germ cell tumor


1.         Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA: a cancer journal for clinicians. 2012;62(4):220-41.
2.         Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. The Journal of urology. 2003;170(1):5-11.
3.         Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. The lancet oncology. 2007;8(9):784-96.
4.         Fosså SD, Aass N, Kaalhus O. Testicular cancer in young Norwegians. Journal of surgical oncology. 1988;39(1):43-63.
5.         Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Annals of internal medicine. 1977;87(3):293-8.
6.         Fosså S, Langmark F, Aass N, Andersen A, Lothe R, Børresen A. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. British journal of cancer. 1990;61(4):639-43.
7.         Roth BJ, Greist A, Kubilis P, Williams S, Einhorn L. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. Journal of Clinical Oncology. 1988;6(8):1239-47.
8.         Bachaud J-M, Berthier F, Soulié M, Malavaud B, Plante P, Rischmann P, et al. Second non-germ cell malignancies in patients treated for stage I–II testicular seminoma. Radiotherapy and oncology. 1999;50(2):191-7.
9.         Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. Journal of clinical oncology. 2013;31(30):3807.
10.       Avril M, Chompret A, Verne-Fourment L, Terrier-Lacombe M, Spatz A, Fizazi K, et al. Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma. Melanoma Research. 2001;11(2):117-22.
11.       Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh urology: expert consult premium edition: enhanced online features and print, 4-volume set: Elsevier Health Sciences; 2011.
12.       Pielop J, Brownell I, Duvic M. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. Wiley Online Library; 2003.
13.       Karuppiah SV, Buchan KG. Primary malignant melanoma: a rare cause of mediastinal mass. The Japanese Journal of Thoracic and Cardiovascular Surgery. 2006;54(9):396-8.
14.       Travis LB, Curtis RE, Fraumeni Jr JF, Boice Jr JD, Storm H, Andersson M, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. Journal of the National Cancer Institute. 1997;89(19):1429-39.
15.       MacKie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. Bmj. 1996;312(7039):1125-8.
16.       Wanderås EH, Fosså S, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. European Journal of Cancer. 1997;33(2):253-62.
17.       Richiardi L, Scélo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, et al. Second malignancies among survivors of germ‐cell testicular cancer: a pooled analysis between 13 cancer registries. International journal of cancer. 2007;120(3):623-31.
18.       Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, et al. The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2000;88(11):2629-35.
19.       Bokemeyer C, Schmoll H-J. Secondary neoplasms following treatment of malignant germ cell tumors. Journal of clinical oncology. 1993;11(9):1703-9.
20.       Raghavan D, Zalcberg JR, Grygiel JJ, Teriana N, Cox KM, McCarthy W, et al. Multiple atypical nevi: a cutaneous marker of germ cell tumors. Journal of clinical oncology. 1994;12(11):2284-7.